• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

66.37 -1.82 (-2.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
Today 12:53 EST
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
Today 12:49 EST
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets. 
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT) Stock Slides After Q4 Earnings Miss ↗
February 19, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
February 12, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation ↗
February 07, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup ↗
February 02, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate ↗
January 12, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup ↗
January 09, 2026
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗
January 01, 2026
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗
December 15, 2025
PTC Therapeutics stock shows strong earnings momentum and a top-rated technical setup, offering a potential breakout opportunity for growth investors. 
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
December 13, 2025
PTC Therapeutics (PTCT) exemplifies a strong growth stock with a bullish technical setup, combining high sales growth, robust margins, and a potential chart breakout. 
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗
December 10, 2025
PTC Therapeutics offers high growth at a fair price, with strong earnings and revenue increases, trading below industry valuations. 
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
December 03, 2025
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? ↗
December 02, 2025
Via The Motley Fool
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
 
Via Benzinga
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
December 03, 2025
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
December 03, 2025
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 03, 2025
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
December 02, 2025
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 ↗
November 29, 2025
Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
November 19, 2025
PTC Therapeutics offers strong growth and solid financials at a fair price, making it an attractive stock for investors seeking affordable expansion opportunities. 
Via Chartmill
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
November 18, 2025
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
November 18, 2025
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows Strong Growth Momentum and Technical Health ↗
November 13, 2025
PTC Therapeutics (PTCT) shows explosive earnings growth of 277% and strong technicals, presenting a high-momentum investment opportunity. 
Via Chartmill
News headline image
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
November 04, 2025
Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage... 
Via MarketMinute
Topics Death
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Mix of Strong Growth and Bullish Technical Setup ↗
October 30, 2025
PTC Therapeutics (PTCT) shows strong growth with 96% revenue surge and a bullish technical breakout pattern, making it a compelling biotech stock. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
October 25, 2025
PTC Therapeutics offers strong growth and attractive valuation metrics, making it a compelling affordable growth stock for investors seeking biotech opportunities. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing ↗
October 02, 2025
PTC Therapeutics (PTCT) offers strong growth with a 96% revenue surge, yet trades at a reasonable P/E of 10.94, making it a compelling GARP investment. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup ↗
September 30, 2025
PTC Therapeutics (PTCT) combines explosive sales growth and strong earnings with an attractive valuation and bullish technical setup for a compelling investment profile. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech ↗
September 11, 2025
PTC Therapeutics (PTCT) offers strong growth & attractive valuation. With revenue up 96% and a low P/E of 10.29, it's a top affordable growth stock pick in biotech. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap